Compare Twist Bioscience Corp (TWST) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs ProShares Ultra Gold ETF — how do they compare? Twist Bioscience Corp trades at $161.84 (market cap $10.08B), while ProShares Ultra Gold ETF trades at $46.52 (market cap $716.59M). The key difference: Twist Bioscience Corp is far larger — about 14.1× ProShares Ultra Gold ETF's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, ProShares Ultra Gold ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and ProShares Ultra Gold ETF for 23 Days on average.
| TWST | UGL | |
|---|---|---|
Market Cap | $10.08B | $716.59M |
Volume | 4,229,037 | 2,592,878 |
Sector | Health | Leveraged / Inverse |
52-Week High | $205.00 | $85.62 |
52-Week Low | $25.45 | $42.79 |
Typical Hold Time | 27 Days | 23 Days |
Enterprise Value | $10.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
UGL trades at $46.47, up 4.59% in the past 24 hours, but technical indicators signal a bearish trend with moving averages and ADX pointing to selling pressure. Key support lies at $44, while resistance is near $46. The stock lacks disclosed financial ratios, limiting fundamental visibility. Recent news highlights gold price volatility driven by Treasury yields and Federal Reserve policy expectations, influencing sentiment around gold-related equities.
The outlook remains cautious due to weak technical momentum and macroeconomic headwinds from rising rates. Investment opportunity hinges on gold price stabilization, but risks include persistent bearish indicators and sensitivity to interest rate changes. Investors should await clearer fundamental data and technical confirmation of a trend reversal before considering entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
